PLUR — Pluri Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1158780 ·
Israel
Last close
$1.01
Market Cap
$12.47M
52W High
$4.87
52W Low
$0.98
ADV30
25,503
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 335,000 | 196,000 | -5,546,000 | -5,880,000 | 24,878,000 | 3,529,000 | 42,312,000 |
| Mar 2026 | 167,000 | 56,000 | -6,536,000 | -5,548,000 | 26,057,000 | 3,419,000 | 39,056,000 |
| Dec 2025 | 198,000 | 86,000 | -6,506,000 | -6,543,000 | 30,596,000 | 4,690,000 | 39,809,000 |
| Sep 2025 | 316,000 | 115,000 | -6,350,000 | -5,850,000 | 33,672,000 | 4,259,000 | 39,319,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-19,588,000
Investing CF
$9,903,000
Financing CF
$13,728,000
CapEx
$-633,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.85
As of
2026-09-13
Balance + Analyst (yfinance extras)
Retained Earnings
$-466,876,000
Inventory
—
Receivables
$219,000
ST Investments
$4,275,000
EBIT TTM
$-24,462,000
Pretax Income TTM
$-25,394,000
Interest Exp TTM
$932,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,016,000
EBITDA
$-24,427,000
Free Cash Flow
$-12,096,750
Enterprise Value
$47,278,788
Total Cash
$7,804,000
Total Debt
$34,914,000
Shares Out
12,344,736
Trailing EPS
$-2.44
Book Value
$-2.13
ROE
—
ROA
-49.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,016,000 | -24,938,000 | -23,821,000 | 24,878,000 | 42,312,000 | -23,036,000 | -19,588,000 |
| Jun 2025 | 1,336,000 | -22,176,000 | -22,583,000 | 38,683,000 | 39,548,000 | -6,842,000 | -18,211,000 |
| Jun 2024 | 326,000 | -22,158,000 | -20,888,000 | 39,527,000 | 34,112,000 | 96,000 | -18,021,000 |
| Jun 2023 | 287,000 | -27,246,000 | -28,321,000 | 50,797,000 | 35,497,000 | 13,355,000 | -22,857,000 |
| Jun 2022 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.90
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| INTS | INTENSITY THERAPEUTICS, INC. | $12.41M | $3.80 | — |
| INAB | IN8BIO, INC. | $11.83M | $1.20 | — |
| CKDXF | Opthea Ltd | $13.68M | $0.01 | — |
| ZIVO | Zivo Bioscience, Inc. | $13.91M | $3.30 | — |
| BCLI | BRAINSTORM CELL THERAPEUTICS INC. | $10.70M | $0.97 | — |
News headlines (Yahoo Finance, 1h cache)
Pluri Announces Pricing of $3.3 Million Registered Direct Offering and Concurrent Private Placement with a Single Healthcare Focused Institutional Investor
2026-08-27 12:00 · Yahoo
Pluri Chairman Alejandro Weinstein’s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30%
2026-07-14 11:00 · Yahoo
Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing
2026-06-02 11:30 · Yahoo
Pluri Inc. (PLUR): One of the Premier Lab-Grown Meat Stocks to Invest In
2026-05-30 15:46 · Yahoo
Pluri Insider Ups Holding During Year
2026-05-28 10:56 · Yahoo
Pluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment
2026-08-17 13:00 · Yahoo
Ever After Foods Acquires Fishway to Expand Integrated Food Production Technology Platform
2026-08-17 12:30 · Yahoo
Pluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK
2026-07-28 12:00 · Yahoo
EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug
2026-05-01 20:00 · Yahoo
Pluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private Placement
2026-03-26 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.